{"id":"venlafaxine-xr-mirtazapine","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Sedation"},{"rate":"15-25","effect":"Weight gain"},{"rate":"10-20","effect":"Nausea"},{"rate":"10-15","effect":"Dizziness"},{"rate":"10-15","effect":"Dry mouth"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Sexual dysfunction"}]},"_chembl":{"chemblId":"CHEMBL1201066","moleculeType":"Small molecule","molecularWeight":"313.87"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Venlafaxine XR is a serotonin-norepinephrine reuptake inhibitor (SNRI) that blocks reuptake of both serotonin and norepinephrine. Mirtazapine is a noradrenergic and specific serotonergic antidepressant (NaSSA) that antagonizes alpha-2 autoreceptors and heteroreceptors, increasing norepinephrine and serotonin release, while also blocking serotonin 5-HT2 and 5-HT3 receptors. Together, they provide complementary mechanisms for treating major depressive disorder.","oneSentence":"This combination increases serotonin and norepinephrine levels in the brain while also enhancing serotonergic signaling through alpha-2 antagonism, used to treat depression.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:39:25.352Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"}]},"trialDetails":[{"nctId":"NCT02893371","phase":"","title":"Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies","status":"TERMINATED","sponsor":"University of New Mexico","startDate":"2016-09","conditions":"Bipolar Disorder","enrollment":1037352},{"nctId":"NCT02058693","phase":"PHASE4","title":"Adjunctive Mixed Salts Amphetamine for Depressed Adults With Incomplete Response to Current Antidepressant Therapy","status":"COMPLETED","sponsor":"Rush University Medical Center","startDate":"2010-12","conditions":"Major Depressive Disorder","enrollment":41},{"nctId":"NCT05737511","phase":"PHASE4","title":"Efficacy of Hydroxyzine for Patients With Panic Disorder","status":"NOT_YET_RECRUITING","sponsor":"Sultan Qaboos University","startDate":"2023-12-30","conditions":"Panic Disorder","enrollment":80},{"nctId":"NCT00564278","phase":"NA","title":"Effects of Adding Motivational Interviewing to Antidepressant Treatment for Hispanic Adults With Depression","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2008-02","conditions":"Depression","enrollment":217},{"nctId":"NCT00742573","phase":"PHASE2","title":"Incorporating Patient Treatment Choice to Improve Treatment Retention in Depressed Hispanics","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2008-08","conditions":"Major Depressive Disorder","enrollment":170},{"nctId":"NCT01916824","phase":"PHASE4","title":"Effects of Treatment on Decision-making in Major Depression","status":"COMPLETED","sponsor":"Emory University","startDate":"2013-08","conditions":"Major Depressive Disorder, Healthy Controls","enrollment":53},{"nctId":"NCT02400346","phase":"PHASE3","title":"Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2015-03","conditions":"Major Depression Disorder","enrollment":132},{"nctId":"NCT00926835","phase":"PHASE4","title":"Effect of Antidepressants on the Treatment for Korean Major Depressive Disorder Patients","status":"TERMINATED","sponsor":"Ministry of Health & Welfare, Korea","startDate":"2009-05","conditions":"Major Depressive Disorder","enrollment":692},{"nctId":"NCT00590863","phase":"PHASE4","title":"Combining Medications to Enhance Depression Outcomes","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2008-03","conditions":"Major Depressive Disorder","enrollment":665}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":18,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["venlafaxine-XR","mirtazapine"],"phase":"marketed","status":"active","brandName":"Venlafaxine XR + Mirtazapine","genericName":"Venlafaxine XR + Mirtazapine","companyName":"National Institute of Mental Health (NIMH)","companyId":"national-institute-of-mental-health-nimh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination increases serotonin and norepinephrine levels in the brain while also enhancing serotonergic signaling through alpha-2 antagonism, used to treat depression. Used for Major depressive disorder.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}